There are multiple factors contributing to the immune system recognizing cancer and properly launching adaptive immune reaction against it. Ardigen research combines the expertise in Artificial Intelligence, Bioinformatics, Cancer Biology, Immunology and Microbiome to deliver technologies that lead to significantly increased response rates to immunotherapies.
Ardigen improves therapeutic outcome by translating microbiome with AI-reinforced biology
Ardigen aids drug development with digital microbiome solutions. By discovering actionable signatures in the
metagenomic haystack, we help you to enter subsequent stages on your way towards an effective pharmaceutical.
At Ardigen, we screen for the most meaningful insights to explain the biology behind the therapeutic potential of
the microbiome. By exploring all the metagenomic information, we reveal previously undiscovered traits.
Ardigen addresses the challenges of drug development, starting with patients’ microbial and clinical data. We
provide insight into the therapy-modulating interplay between host and microbiome, by exploring the functional
potential of commensal microbiota. In the process of revealing microbial signatures, we decode biological
findings to achieve clinical benefits.
Our research is supported by a broad network of clinical and academic collaborators, orchestrated by Ardigen’s Clinical Operations unit.
Effective shared and personalized cancer vaccine design proved to be challenging. The therapies in multiple
clinical trials failed to stimulate immune responses strong enough to light the disease, and in a few cases caused
severe toxicity towards self-antigens. To solve these challenges, Ardigen developed ArdImmune Vax – an Artificial
Intelligence-driven vaccine design platform. The speed of ArdImmune Vax enables clinically relevant windows to
be reached even with most demanding therapies. ArdImmune Vax can be used beyond cancer and move viral
vaccine design into the era of AI.
ArdImmune Vax uses next generation sequencing of cancer tissue and healthy samples to extract information about candidate therapeutic neoepitopes. These neoepitopes are evaluated for their properties including the potential to induce specific and effective T cell responses, safety and manufacturability. The success of the cancer treatment also depends on efficiently covering the clonal structure of the tumor, which we consider in ArdImmune Vax.
Quickly prepared prioritized list of neoepitopes enables therapy development optimized for effectiveness, cost and speed of delivery.
Preparing thousands of cells bearing the same TCR, which are to be infused into patient, you need to be sure it will find its target. You are also on the clock when screening for the right TCR. Therefore, accurate prioritization of peptide-HLA pairs is crucial for you to meet your timeline with an effective therapy.
The same is valid for the selection of epitopes to be loaded into dendritic cells that afterwards are used as a delivery system.
Ardigen in silico platform will help you reach these goals.